- Oruka Therapeutics announced a **$180 million private placement** (PIPE financing) led by **Viking Global Investors**.  **[907654_0001213900-25-090129_ea025786501ex99-1_oruka.htm:0]** 
- The financing involved the sale of **10,933,405 shares of common stock at a purchase price of $15.00 per share** and **pre-funded warrants to purchase 1,066,666 shares at a price of $14.999 per pre-funded warrant**.  **[907654_0001213900-25-090129_ea025786501ex99-1_oruka.htm:0]**  The closing of the Private Placement occurred on **September 19, 2025**.  **[907654_0001213900-25-090129_ea0257865-8k_oruka.htm:1]** 
- The company intends to use the net proceeds for **research and development, general corporate expenses, and working capital needs**.  **[907654_0001213900-25-090129_ea025786501ex99-1_oruka.htm:0]**  Oruka expects its cash to fund operations for at least one year following ORKA-002 Phase 2 and ORKA-001 EVERLAST-B Phase 2b data readouts in **2027**.  **[907654_0001213900-25-090129_ea025786501ex99-1_oruka.htm:0]** 
- Following the transaction, approximately **67.1 million shares** of the Company’s Common Stock and Common Stock equivalents will be issued and outstanding.  **[907654_0001213900-25-090129_ea025786501ex99-1_oruka.htm:0]**

Oruka Therapeutics (ORKA)